Publicaciones en las que colabora con Ana Fernández Santander (17)

2023

  1. HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

    Cancers, Vol. 15, Núm. 3

2022

  1. FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 2

2021

  1. Genetic variants of ANGPT1, CD39, FGF2 and MMP9 linked to clinical outcome of bevacizumab plus chemotherapy for metastatic colorectal cancer

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-16

  2. Mir-7, mir-10a and mir-143 expression may predict response to bevacizumab plus chemotherapy in patients with metastatic colorectal cancer

    Pharmacogenomics and Personalized Medicine, Vol. 14, pp. 1263-1273

  3. Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer

    Frontiers in Oncology, Vol. 11

2020

  1. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

    World journal of gastroenterology, Vol. 26, Núm. 16, pp. 1979-1986

  2. Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

    Journal of Oncology, Vol. 2020

2018

  1. Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types

    Oncology Letters, Vol. 16, Núm. 6, pp. 6950-6959

  2. Pharmacogenetics of ugt genes in North African populations

    Pharmacogenomics Journal

  3. UDP-glucuronosyltransferase genetic variation in North African populations: a comparison with African and European data

    Annals of Human Biology, Vol. 45, Núm. 6-8, pp. 516-523

2017

  1. Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene

    Pharmacogenomics Journal

2016

  1. Cytochrome and sulfotransferase gene variation in north African populations

    Pharmacogenomics, Vol. 17, Núm. 13, pp. 1415-1423

2015

  1. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia

    International Journal of Biological Markers, Vol. 30, Núm. 1, pp. e148-e151

  2. Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients

    PLoS ONE, Vol. 10, Núm. 7

  3. North African genetic variation of cytochrome and sulfotransferase genes

    International Journal of Modern Anthropology, Vol. 1, Núm. 8, pp. 13

2013

  1. Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

    PLoS ONE, Vol. 8, Núm. 7

  2. Tamoxifen therapy in breast cancer: Do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?

    International Journal of Biological Markers, Vol. 28, Núm. 4